DAPAHENZ S 5/100 10S

About

Dapahenz S 5/100 is a combination medication containing Dapagliflozin and Sitagliptin. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting glucose excretion in the urine. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's natural ability to lower high blood glucose levels by increasing the levels of incretin hormones (GLP-1 and GIP). These hormones increase insulin synthesis and release from pancreatic beta cells and decrease glucagon secretion from pancreatic alpha cells, particularly in a glucose-dependent manner.

This combination therapy offers a complementary approach to managing type 2 diabetes. Dapagliflozin acts independently of insulin, while Sitagliptin improves pancreatic islet function. Together, they provide robust glycemic control, addressing multiple pathophysiological defects of type 2 diabetes. The combination can lead to significant reductions in HbA1c, with the added benefits of Dapagliflozin's cardiovascular and renal protection, and Sitagliptin's generally favorable tolerability profile.

Uses

• Management of type 2 diabetes mellitus.
• Improvement of glycemic control in adults.
• Used as an adjunct to diet and exercise.
• For patients inadequately controlled on monotherapy.

Directions For Use

Take orally once daily, with or without food, as directed by your physician. Swallow the tablet whole with water.

Benefits

• Provides comprehensive blood glucose control.
• Enhances natural insulin release.
• Reduces glucagon secretion.
• Offers cardiovascular and renal protection.
• Low risk of hypoglycemia when used alone.
• Convenience of a single tablet combination.

Side Effects

• Urinary tract infections (UTIs)
• Genital yeast infections
• Nasopharyngitis
• Headache
• Diarrhea
• Nausea
• Increased urination
• Thirst
• Dizziness
• Ketoacidosis (rare, Dapagliflozin-related)
• Pancreatitis (rare, Sitagliptin-related)
• Joint pain (arthralgia)

Safety Measures

• Alcohol - Limit alcohol intake as it can increase the risk of ketoacidosis and dehydration, especially when combined with this medication.
• Pregnancy - Generally not recommended during pregnancy, particularly in the second and third trimesters. Consult a doctor to discuss alternatives.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if the drug passes into breast milk and could harm the infant. Consult a doctor.
• Liver - Use with caution in patients with severe liver impairment; dose adjustments may be necessary.
• Kidney - Dose adjustment for Sitagliptin may be required in patients with moderate to severe renal impairment. Dapagliflozin efficacy is reduced in severe impairment.
• Lung - Generally safe for use in patients with lung conditions; no specific contraindications related to pulmonary function.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.